Inhibitory effect of myricetin on the metastasis of human renal cell carcinoma

TAN Haisong; YE Chen; WU Dengshuang; BAO Yi; LIU Bing; HE Yi; WANG Linhui

doi:10.3969/j.issn.1006-0111.2017.03.009

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To evaluate the role of myricetin in the metastasis of human renal cancer ACHN cells both in vitro and in vivo. Methods With different concentration of myricetin (25, 50, 100 μmol/L) acting on ACHN cells, the cell viability, migration and invasion were respectively measured with CCK-8 assay, wound healing migration assay and Transwell invasion assay in vitro. A lung metastatic model for human renal cell carcinoma was developed by tail vein injection with ACHN cells. The effect of myricetin on the metastasis of renal cell carcinoma was explored by intraperitoneal injection of myricetin in vivo. After 6 weeks, the micro metastases of the lungs in nude mice was examined. Results Compared to the control group, CCK-8 assay showed that the cell viability was significantly lower in the myricetin group at the concentration of 50 μmol/L for 24 h (P=0.019). The inhibitory effect became more significant with the increase in drug concentration or action time. In addition, myricetin also inhibits the migration and invasion of ACHN cells in a dose dependent manner. Intraperitoneal injection of myricetin significantly reduced the number of the micro metastases of renal cell carcinoma in the lungs of nude mice. Conclusion Myricetin effectively inhibits the cell viability, migration and invasion of human renal cancer ACHN cells. It has the potential therapeutic value in the treatment of renal cell carcinoma.

Inhibitory effect of myricetin on the metastasis of human renal cell carcinoma

1. Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

2. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

3. Department of Urology, Jiaxing First Hospital, Jiaxing 314000, China

Received Date: 2017-02-03

Rev Recd Date: 2017-03-28

Key words:

Abstract: Objective To evaluate the role of myricetin in the metastasis of human renal cancer ACHN cells both in vitro and in vivo. Methods With different concentration of myricetin (25, 50, 100 μmol/L) acting on ACHN cells, the cell viability, migration and invasion were respectively measured with CCK-8 assay, wound healing migration assay and Transwell invasion assay in vitro. A lung metastatic model for human renal cell carcinoma was developed by tail vein injection with ACHN cells. The effect of myricetin on the metastasis of renal cell carcinoma was explored by intraperitoneal injection of myricetin in vivo. After 6 weeks, the micro metastases of the lungs in nude mice was examined. Results Compared to the control group, CCK-8 assay showed that the cell viability was significantly lower in the myricetin group at the concentration of 50 μmol/L for 24 h (P=0.019). The inhibitory effect became more significant with the increase in drug concentration or action time. In addition, myricetin also inhibits the migration and invasion of ACHN cells in a dose dependent manner. Intraperitoneal injection of myricetin significantly reduced the number of the micro metastases of renal cell carcinoma in the lungs of nude mice. Conclusion Myricetin effectively inhibits the cell viability, migration and invasion of human renal cancer ACHN cells. It has the potential therapeutic value in the treatment of renal cell carcinoma.

HTML

Reference (15)

[1]	惠丽娜, 范开席, 徐忠法. 肾细胞癌的治疗方法及应用现状[J]. 山东医药, 2015, 55(14): 102-103.
[2]	Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?[J]. Eur Urol, 2010, 58(4): 588-595.
[3]	Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review[J]. Cancer Treat Rev, 2008, 34(3): 193-205.
[4]	刘磊. 转移性肾细胞癌靶向药物治疗的现状[J]. 国际泌尿系统杂志, 2015, 35(6): 923-926.
[5]	吴少花, 陈君, 刘亚萌, 等. 杨梅素抗肿瘤活性研究进展[J]. 吉林医药学院学报, 2015, 36(5): 381-383.
[6]	刘雪丽, 周学锋, 王君瑜, 等. 中药抗肿瘤作用机制研究进展[J]. 中国药师, 2016, 19(6): 1158-1162.
[7]	Feng J, Chen X, Wang Y, et al. Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells[J]. Mol Cell Biochem, 2015, 408(1-2): 163-170.
[8]	Huang H, Chen AY, Ye X, et al. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway[J]. Int J Oncol, 2015, 47(4): 1494-1502.
[9]	Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo[J]. Nutr Cancer, 2012, 64(4): 599-606.
[10]	Seydi E, Rasekh HR, Salimi A, et al. Myricetin selectively induces apoptosis on cancerous hepatocytes by directly targeting their mitochondria[J]. Basic Clin Pharmacol Toxicol, 2016, 119(3): 249-258.
[11]	郭海清, 任锋, 陈亚利, 等. 杨梅素对HepG2细胞凋亡的影响[J]. 北京医学, 2014, 36(9): 748-751,799.
[12]	李有富, 李魏林. 杨梅素对肝癌细胞Bel-7402裸鼠移植瘤的抑制作用[J]. 中国医药导报, 2015, 12(31): 44-47.
[13]	李有富, 李辉, 韩涛, 等. 杨梅素诱导人宫颈癌HeLa细胞凋亡及凋亡通路的研究[J]. 西北药学杂志, 2016, 31(3): 270-274.
[14]	刘师兵, 陈君, 吴少花, 等. 杨梅素诱导HeLa细胞凋亡的形态学研究[J]. 吉林医药学院学报, 2015, 36(6): 418-421.
[15]	Shih YW, Wu PF, Lee YC, et al. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway[J]. J Agric Food Chem, 2009, 57(9): 3490-3499.

Message Board

Inhibitory effect of myricetin on the metastasis of human renal cell carcinoma

doi: 10.3969/j.issn.1006-0111.2017.03.009

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views